title: Clinical evaluation of 3Mix and Vitapex as treatment options for pulpally involved primary molars.
abstract: OBJECTIVE
  The aim of this study was to compare the clinical and radiographic success of 3Mix and Vitapex((R)) for root canal treatment of pulpally involved primary molars.
  
  
  METHODS
  Fifty teeth from 37 healthy children aged 3-8 years with pulpally involved primary molars needing root canal procedures were treated with 3Mix or Vitapex((R)) before restoration with stainless steel crowns. The research employed a prospective single-blinded randomized design. The subjects were followed up clinically and radiographically at 6 and 12 months, respectively. The outcome was compared using a Z-test with a significance level of 0.05.
  
  
  RESULTS
  Both groups showed 100% and 96% clinical success at 6 and 12 months, respectively. At 6 months, radiographic success of 3Mix and Vitapex((R)) was 84% and 80%, respectively, and at 12 months, radiographic success of 3Mix and Vitapex((R)) was 76% and 56%, respectively. Considering the radiographic findings at the end of 6 and 12 months, no statistically significant differences were found between the two groups (P = 0.356 and 0.068, respectively).
  
  
  CONCLUSIONS
  3Mix and Vitapex((R)) can be used as a root canal treatment agent in pulpally involved primary teeth.
authors.affiliation: Department of Pediatric Dentistry, Faculty of Dentistry, Mahidol University, Bangkok, Thailand. dtsnk@mucc.mahidol.ac.th
authors.forename: Siriruk
authors.initials: S
authors.lastname: Nakornchai
authors.forename: Panit
authors.initials: P
authors.lastname: Banditsing
authors.forename: Nattida
authors.initials: N
authors.lastname: Visetratana
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002126:Calcium Hydroxide / Q000737:chemistry / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000008:administration & dosage; D003790:Dental Pulp Necrosis / Q000188:drug therapy / Q000601:surgery*; D004338:Drug Combinations; D005500:Follow-Up Studies; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage; D008911:Minocycline / Q000008:administration & dosage; D008963:Molar; D009824:Ointments / Q000008:administration & dosage / Q000737:chemistry; D011092:Polyethylene Glycols / Q000008:administration & dosage; D019946:Propylene Glycol / Q000008:administration & dosage; D011446:Prospective Studies; D011859:Radiography; D012387:Root Canal Filling Materials / Q000737:chemistry / Q000627:therapeutic use*; D012390:Root Canal Therapy / Q000379:methods*; D012828:Silicones / Q000737:chemistry / Q000627:therapeutic use; D016037:Single-Blind Method; D014094:Tooth, Deciduous / Q000187:drug effects / Q000601:surgery*; D019553:Tooth, Nonvital / Q000000981:diagnostic imaging; D016896:Treatment Outcome
chemical_list: C551230:3Mix ointment; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D009824:Ointments; D012387:Root Canal Filling Materials; D012828:Silicones; C029584:calcium hydroxide, iodoform, silicone oil drug combination; D008795:Metronidazole; D011092:Polyethylene Glycols; D002939:Ciprofloxacin; D019946:Propylene Glycol; D008911:Minocycline; D002126:Calcium Hydroxide